MedTrace Logo

BOTOX® (Onabotulinumtoxin A) Injection(s) as a Treatment for Carpal Tunnel Syndrome

NCT02070302 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2017-09-27

Study results available
· View outcomes & findings →

Summary

This study will be a prospective double blind controlled randomized trial of ten patients diagnosed with Carpal Tunnel Syndrome (CTS). The study will be completed at offices of medical practices in Arizona. Patients who meet inclusion criteria will be randomly distributed into two groups: a BOTOX® (onabotulinumtoxin A) injection group and a Normal Saline Injection (NS) (Placebo group). Each group will consist of five randomly assigned individuals.

Conditions

  • Carpal Tunnel Syndrome

Interventions

DRUG

Botulinum Toxin Type A

40 units of BOTOX® (onabotulinumtoxin A) divided into two injection sites of 20 units each

DRUG

Placebo

Placebo (Normal Saline) divided into 2 injections of .4cc each

Sponsors & Collaborators

  • Allergan

    collaborator INDUSTRY

  • Benjamin Sucher

    lead OTHER

Principal Investigators

  • Benjamin Sucher, DO · Arizona Arthritis & Rheumatology Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2016-02-29
Completion
2016-02-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02070302 on ClinicalTrials.gov